Nitroheterocyclic derivatives: privileged scaffold for drug development against Chagas disease
- 32 Downloads
Chagas disease or American trypanosomiasis is a major public health problem in Latin America. Approximately seven million people are currently infected worldwide. Despite the efforts to develop new drugs, only two nitroheterocyclic drugs (nifurtimox and benznidazole) are available for the treatment of Chagas disease, These drugs have been available since the 1970s, and no new drugs have been approved. Due to the lack of alternatives for the treatment of this disease, this review describes recent advances (2013–2019) concerning nitroheterocyclic compounds with activity against T. cruzi parasites, as well as new perspectives for future research.
KeywordsChagas disease T. cruzi Nitro compounds New drugs
This work was financed in part by the Coordenação de Aperfeiçoamento Pessoal de Nível Superior—Brasil (CAPES)—Finance code 001. Moreover, the authors would like to thank the Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP—2016/10847-9) for the research fellowship assistance.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- Andrade MC, Oliveira MDF, Nagao-Dias AT et al (2013) Clinical and serological evolution in chronic Chagas disease patients in a 4-year pharmacotherapy follow-up: a preliminary study. Rev Soc Bras Med Trop 46: https://doi.org/10.1590/0037-8682-1646-2013
- Britta EA, Scariot DB, Falzirolli H et al. (2015) 4-Nitrobenzaldehyde thiosemicarbazone: a new compound derived from S-(-)-limonene that induces mitochondrial alterations in epimastigotes and trypomastigotes of Trypanosoma cruzi. Parasitology 142:978–988. https://doi.org/10.1017/S0031182015000141 CrossRefPubMedGoogle Scholar
- DNDi (2019) Drugs for neglected diseases initiative (DNDi), Neglected Tropical Diseases. https://www.dndi.org/diseases-projects/chagas/. (Accessed 21 August 2019).
- Ferreira EI (2012) Planejamento de Fármacos na Área de Doença de Chagas: Avanços e Desafios Planejamento de Fármacos na Área de Doença de Chagas. Avanços e Desafios 4:225–246Google Scholar
- Fonseca-Berzal C, Ibáñez-Escribano A, Reviriego F et al. (2016) Antichagasic and trichomonacidal activity of 1-substituted 2-benzyl-5-nitroindazolin-3-ones and 3-alkoxy-2-benzyl-5-nitro-2H-indazoles. Eur J Med Chem 115:295–310. https://doi.org/10.1016/j.ejmech.2016.03.036 CrossRefPubMedGoogle Scholar
- Francisco AF, Lewis MD, Jayawardhana S et al. (2015) Limited ability of posaconazole to cure both acute and chronic trypanosoma cruzi infections revealed by highly sensitive in vivo imaging. Antimicrob Agents Chemother 59:4653–4661. https://doi.org/10.1128/AAC.00520-15 CrossRefPubMedPubMedCentralGoogle Scholar
- Guido RVC, Ferreira EI, Nassute JC, Varanda EA, Chung MC (2001) Diminuição da atividade mutagênica do pró-fármaco NFOH-121 em relação ao nitrofural (nitrofurazona). Rev Ciências Farm 22:319–333Google Scholar
- Maya JD, Orellana M, Ferreira J et al (2010) Chagas disease: present status of pathogenic mechanisms and chemotherapy. Biol Res 323–231. https://doi.org/10.4067/S0716-97602010000300009.
- Morillo CA, Marin-Neto JA, Avezum A et al. (2015) Randomized trial of benznidazole for chronic chagas’ cardiomyopathy. N Engl J Med 2015:1295–1306. 10.1056/NEJMoa1507574Google Scholar
- Palace-Berl F, Pasqualoto KFM, Zingales B et al. (2018) Investigating the structure-activity relationships of N’-[(5-nitrofuran-2-yl) methylene] substituted hydrazides against Trypanosoma cruzi to design novel active compounds. Eur J Med Chem 144:29–40Google Scholar
- Scarim CB, de Andrade CR, da Rosa JA et al. (2018) Hydroxymethylnitrofurazone treatment in indeterminate form of chronic Chagas disease: reduced intensity of tissue parasitism and inflammation—a histopathological study. Int J Exp Pathol 99:236–248. https://doi.org/10.1111/iep.12289 CrossRefPubMedPubMedCentralGoogle Scholar
- World and Health Organization (WHO) (2019) Neglected tropical diseases. World and Health Organization (WHO). http://www.who.int/neglected_diseases/diseases/en/. Accessed 21 August 2019
- WHO (2002). Control of Chagas disease: second report of the WHO expert committee. World Health Organization (2000: Brasilia, Brazil). Geneva, World Health Organization. 905:109Google Scholar